Sat, Jul 26, 2014, 4:07 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Vical Incorporated Message Board

gofordna 2 posts  |  Last Activity: Aug 7, 2013 8:22 AM Member since: Sep 26, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Pumpers and Bashers

    by briannajor Aug 7, 2013 1:14 AM
    gofordna gofordna Aug 7, 2013 8:22 AM Flag

    My alias shows I'm a believer. I try not to make it personal but to stick to my view of facts and the science that Vical's stock value is based on. To that end, I urge others to read thoughtful articles and data, ie to do their own due diligence as investors. Traders have and will continue playing this stock until a breakout happens beyond the $2.50 to $4.50 channel this stock has been stuck in for years as it waits for validation in human (not fish or dog) trials. IMO validation is imminent, thank God.
    I just re-read the Ted Cohen Seeking Alpha interview from July with a credible clinical trial stat geek. You should too. I truly believe there's a better than 50:50 chance that the death event number that Vical aimed for is low -- below 275. If I'm right, there's a very good chance Vical stock price will soar, provided the p value (showing separation between treatment and control arms due to the Allovectin drug) is strong. I'm willing to take this calculated risk, having waited patiently for the data finally to be locked and reported.

    Frankly, there's way too much noise on this MB and personal banter. Yes, I'm bullish and holding a nice chunk of shares that I intend to sell in stages as the share price moves upward. Right now I'm above water with my holdings so everything north of this price is long term profit. And to see what kind of proof I see that Allovectin works, just look at the photos shown on the 2011 ASCO Poster one pager available on Vical's own web site. This is public disclosure showing how distal lung tumors shrunk after at least 2 Allovectin injection cycles in the Phase 2 study.

    Sentiment: Hold

  • Reply to

    Conference call

    by pantelonesdelapoopoo Aug 2, 2013 11:03 AM
    gofordna gofordna Aug 2, 2013 11:23 AM Flag

    My understanding is hazard ratio shows how the survival curves separate with statistical significance a key for FDA approval. And history tells us that Vical's cancer platform extends life for responders. IMO we may NOT have reached MEDIAN deaths on the Allovectin side......a very good thing.....IF we get stat sig on hazard ratio.

VICL
1.25-0.03(-2.34%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.